Psychological impact of COVID-19 pandemic on Parkinson's disease patients

Tufail, Muhammad; Wu, Changxin

doi:10.1016/j.heliyon.2022.e09604

Cited by 5 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During zero-COVID (year 2022), sleep disturbance was identified in 68.9% of PD patients, and PD patients had significantly higher scores of PSQI and HADS than healthy controls [ 21 ]. Another questionnaire study about the emotional and physiological symptoms of PD patients during the COVID-19 pandemic (year 2022) enrolled 94 PD patients and 188 controls [ 22 ]. It found that a significant number of PD patients were depressed and the major reason was COVID-19.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey

Huang,

Tan,

Chen

et al. 2024

Transl Neurodegener

View full text Add to dashboard Cite

Background Little is known about the impact of the COVID-19 pandemic on patients with Parkinson’s disease (PD) at different stages of the pandemic. This study aims to assess the lives and disease status of PD patients during the zero-COVID policy period and after ending the zero-COVID policy. Methods This multicenter cross-sectional study included two online surveys among PD patients in China, from May 30 to June 30 in 2022 and from January 1 to February 28 in 2023, respectively. The survey questionnaires contained four sections: (1) status of COVID-19 infection; (2) impact on motor and non-motor symptoms; (3) impact on daily and social lives; and (4) impact on PD disease management. Results A total of 1764 PD patients participated in the first online survey, with 200 patients having lockdown experience and 3 being COVID-19-positive (0.17%). In addition, 537 patients participated in the second online survey, with 467 patients having COVID-19 infection (86.96%). (1) During zero-COVID, all of the COVID-19-positive patients had mild symptoms of COVID-19 and no death was reported. After zero-COVID, 83.51% of the COVID-19-positive patients had mild symptoms. The overall death rate and inpatient mortality rate of COVID-19-positive PD patients were 3.21% and 30.00%, respectively. (2) During zero-COVID, 49.43% of PD patients reported worsening of PD-related symptoms (lockdown vs. unlockdown, 60.50% vs. 48.02%, P = 0.0009). After zero-COVID, 54.93% of PD patients reported worsening of PD-related symptoms (COVID-19 positive vs. COVID-19 negative, 59.31% vs. 25.71%, P < 0.0001). (3) During zero-COVID, 62.36% of patients felt worried, and ‘limited outdoor activities’ (55.39%) was the top reason for mental health problems. After zero-COVID, 59.03% of patients felt worried, with ‘poor health’ (58.10%) being the top reason. The PD patients tended to change their daily activities from offline to online, and their economic and caregiver burdens increased both during and after zero-COVID. (4) Most PD patients would like to choose online rehabilitation during (69.56%) and after zero-COVID (69.27%). The demand for online medication purchasing also increased during (47.00%) and after zero-COVID (26.63%). Conclusions The COVID-19 pandemic aggravated the motor and non-motor symptoms of PD patients either during or after the zero-COVID policy period. The PD patients also experienced prominent mental health problems, changes in daily activities, and increases in economic and caregiver burdens. The COVID-19 pandemic has changed ways of PD management with increasing demands for online medication purchasing and rehabilitation.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It found that a significant number of PD patients were depressed and the major reason was COVID-19. Among the physiological symptoms, low energy, restlessness, and avoiding social interaction were significantly higher in PD patients [ 22 ]. Our data were consistent with previous studies.…”

Section: Discussionmentioning

confidence: 99%

Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey

Huang,

Tan,

Chen

et al. 2024

Transl Neurodegener

View full text Add to dashboard Cite

show abstract

“…A study including 5,429 PD patients revealed the worsening of non-motor symptoms such as sleeps-disturbances, cognitive function, autonomic function, mood disorders, appetite disorders and pain ( 92 ). Also, emotional symptoms of stress due to COVID-19 concerns are not negligible in PD patients ( 93 ).…”

Section: Shared Clinical Features Between Covid-19 and Pdmentioning

confidence: 99%

COVID-19 and neurological disorders: what might connect Parkinson’s disease to SARS-CoV-2 infection

et al. 2023

View full text Add to dashboard Cite

SARS-CoV-2 infection leading to Coronavirus disease 19 (COVID-19) rapidly became a worldwide health emergency due to its elevated infecting capacity, morbidity, and mortality. Parkinson’s disease (PD) is the second most common neurodegenerative disorder and, nowadays the relationship between SARS-CoV-2 outbreak and PD reached a great interest. Apparently independent one from the other, both diseases share some pathogenetic and clinical features. The relationship between SARS-CoV-2 infection and PD is complex and it depends on the direction of the association that is which of the two diseases comes first. Some evidence suggests that SARS-CoV-2 infection might be a possible risk factor for PD wherein the exposure to SARS-CoV-2 increase the risk for PD. This perspective comes out from the increasing cases of parkinsonism following COVID-19 and also from the anatomical structures affected in both COVID-19 and early PD such as olfactory bulb and gastrointestinal tract resulting in the same symptoms such as hyposmia and constipation. Furthermore, there are many reported cases of patients who developed hypokinetic extrapyramidal syndrome following SARS-CoV-2 infection although these would resemble a post-encephalitic conditions and there are to date relevant data to support the hypothesis that SARS-CoV-2 infection is a risk factor for the development of PD. Future large, longitudinal and population-based studies are needed to better assess whether the risk of developing PD after COVID-19 exists given the short time span from the starting of pandemic. Indeed, this brief time-window does not allow the precise estimation of the incidence and prevalence of PD after pandemic when compared with pre-pandemic era. If the association between SARS-CoV-2 infection and PD pathogenesis is actually putative, on the other hand, vulnerable PD patients may have a greater risk to develop COVID-19 being also more prone to develop a more aggressive disease course. Furthermore, PD patients with PD showed a worsening of motor and non-motor symptoms during COVID-19 outbreak due to both infection and social restriction. As well, the worries related to the risk of being infected should not be neglected. Here we summarize the current knowledge emerging about the epidemiological, pathogenetic and clinical relationship between SARS-CoV-2 infection and PD.

show abstract

Navigating mental health in a post-COVID world: the experience of colorectal cancer patients

Tufail

2023

Support Care Cancer

View full text Add to dashboard Cite

Psychological impact of COVID-19 pandemic on Parkinson's disease patients

Cited by 5 publications

References 44 publications

Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey

Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey

COVID-19 and neurological disorders: what might connect Parkinson’s disease to SARS-CoV-2 infection

Navigating mental health in a post-COVID world: the experience of colorectal cancer patients

Contact Info

Product

Resources

About